📩Our final newsletter of 2025 is out! As we close 2025, we also say farewell to our CEO, @marcbonten.bsky.social. We are proud of what we have achieved together over the years & look ahead with confidence to 2026, welcoming @lenniederde.bsky.social onboard! Read more & subscribe: bit.ly/Dec25Ecraid

The rationale & design of the #PNEUMO study Europe was recently published! 👉 bit.ly/3MBR6d4 Now in its final year, the studies primary goal is to estimate the incidence of pneumococcal #pneumonia & serotype prevalence among adults in Europe. #ClinicalTrials #InfectiousDiseases #ResearchSky #IDSky

Join the Ecraid Foundation Science Meeting on 2 February 2026 in Utrecht! This two-day academic event brings together leading experts, researchers & infectious disease opinion leaders from across Europe to advance clinical research in ID. More info & tickets: www.eventbrite.nl/e/ecraid-fou...

Trainings, talent & top science: the last Ecraid Learning Newsletter of the year is out! Filled to the brim with exciting courses, testimonials from participants at past ones, freshly-published science and interesting interviews & blogs! 👉🏽https://bit.ly/LearningDecEcraid

Ecraid joins the #PrIMAVeRa_AMR Consortium to accelerate #AMR modelling! This strategic partnership is a powerful step forward in the fight against #AntimicrobialResistance. 👉🏽Learn more about this vital collaboration & its impact on public health: www.ecraid.eu/news/ecraid-... #StopSuperbugs

Ventilator-associated pneumonia can be a challenge to study in traditional randomised controlled trials due to low patient and event numbers. This recent paper explores whether adaptive trial designs can make VAP prevention trials more efficient link.springer.com/article/10.1...

Proud to be a part of the PrIMAVeRA consortium and contribute to developing comprehensive mathematical models to predict the impact of #vaccines and mAbs on reducing the burden of #anitmicrobialresistance 👇 🎉

📩 Our latest newsletter is out! We’re thrilled to welcome our new CEO, @lenniederde.bsky.social, marking a fresh chapter in Ecraid’s journey. Other updates in this edition: ✅ ECRAID-Base: new publications ✅ ECRAID-Prime: launch of third treatment arm And more… 📫 Subscribe now: bit.ly/NovEcraid

We are very pleased to announce Lennie Derde as Ecraid's new Chief Executive Officer effective 1 January 2026. She will succeed Ecraid’s co-founder @marcbonten.bsky.social Read more 👉 ecraid.eu/articles/len... @umcutrecht.bsky.social @ec.europa.eu @horizoneu.bsky.social

💉Early BCG vaccination could save newborn lives. A new RCT from India shows a nearly 20% drop in neonatal mortality simply by administering vaccines earlier. 🔗 Read the latest blog post by @marcbonten.bsky.social: letstalkscience.eu/2025/11/04/l... Join the discussion 👇🏽

💡 The Penta BFA provides recognition & funding to individuals driving change in maternal & child health. Honour a leader who is advancing equitable health outcomes & combatting infectious disease. Deadline for nominations has been extended to 15 November! 👉🏼 Submit your nomination: penta-id.org/bfa/

🚨 1 in 6 bacterial infections is now antibiotic-resistant. The new WHO GLASS Report demands immediate action. Ecraid is Europe's answer. We're bridging the crisis-to-solution gap. 👉🏽Read how: bit.ly/WHOGLASS

🦠 New tool to track #antibioticresistance: the Emerging Resistance Index (ERI). 💡Using data from 38 surveillance systems across Europe, researchers found rapid resistance emerging to all new Gram-negative antibiotics. The ERI could help guide surveillance & policy! 👉Read the article bit.ly/4hgk51g

Meet Eveline Verheijen, our new Site Management Organisation (SMO) Manager! 🔬 Eveline leads our vaccination site in Utrecht - one of the top-performing study sites in NL. Her focus on collaboration, quality & efficiency helps accelerate clinical research. 🔎Read the full interview: bit.ly/SMO-Eveline

💡 The Penta Brighter Future Award provides essential recognition and funding to individuals driving change in maternal and child health. Honour a leader who is advancing equitable health outcomes and combatting infectious disease at the community level. 👉🏼 Submit your nomination: penta-id.org/bfa/

📩 Our latest newsletter is out! Discover significant developments at Ecraid, including the launch of our new campaign to foster strategic collaborations, #PartnerForImpact! 📫 Stay informed, subscribe now bit.ly/43kBWhJ #PartnerWithEcraid #ClinicalResearch #InfectiousDiseases #Education #Knowledge

@marcbonten.bsky.social has dedicated his career to advancing #clinicalmicrobiology & combatting #antimicrobialresistance. In his new role as Vice-Dean Education at @umcutrecht.bsky.social he continues to inspire the next generation of healthcare scientists & researchers: ecraid.eu/articles/edu...

The #ECDC report on C. auris shows gaps in EU surveillance & IPC. Ecraid is built to fill them: - Warm-base network for faster diagnosis, prevention, & treatment. - Single-access infrastructure breaks research silos. We strengthen the defense against future #AMR threats: bit.ly/PartnerForIm...

Which antibiotic works best for treating moderate to severe community-acquired pneumonia (CAP) 🫁 ? A commentary in Clinical Microbiology and Infection emphasises the urgent need for stronger evidence - because patients deserve better 👇🏼 @escmid.bsky.social @cmicomms.bsky.social

On 15-SEP, the annual #PNEUMO EU F2F meeting with Ecraid’s operational team and funder MSD took place. It was a fruitful meeting held at MSD headquarters in Haarlem, with a very nice tour around their facility. Thanks to Kelly Johnson & #MSD NL for the hospitality & for continuous collaboration!

📩 In our latest newsletter you can read more about Ecraid’s September highlights including studies updates and other milestones! 👉🏽 Meet us in Amsterdam at the ERS Congress & World Vaccine Congress. Book a meeting with our team: [email protected] 📫 Stay informed, subscribe now: bit.ly/EcraidNewsSe...

🦠 Can respiratory viruses like SARS-CoV-2 and influenza reactivate dormant cancer cells? Although widely regarded as a scientific breakthrough and despite firm conclusions, some emphasised that cancer survivors should not be alarmed yet. Read the latest blog post by @marcbonten.bsky.social

Our Education Newsletter is out now! Packed with opportunities and inspiration for early-career researchers and beyond: upcoming postgraduate courses, new scientific papers, a webinar recording you may have missed, & more resources to boost your knowledge 👉 mailchi.mp/ecraid/ecrai...

Don't miss this chance to attend this course featuring insightful lectures, interactive afternoon workshops and invaluable network opportunities with other researchers and experts from across Europe & beyond 👇 www.escmid.org/event-detail... @escmid.bsky.social @umcutrecht.bsky.social

We are looking for a visionary Chief Executive Officer to lead Ecraid into its new chapter. If you are a purpose-driven and people-centred leader with bold ideas, an entrepreneurial spirit and a pan-European mindset, we’re looking for you! More info 👉 www.ecraid.eu/careers

📩In our latest newsletter you can read more about our upcoming educational opportunities and get the latest updates on publications and study milestones. 👉🏽We're hiring a Chief Executive Officer! Are you interested? Read more in our newsletter. 📫Stay informed, subscribe now: bit.ly/07NewsEcraid

What are ethical, administrative, regulatory and logistical hurdles for delivery of RCTs & can these be qualified? Hot off the presses, this article in @jamanetworkopen.com by [email protected], the REMAP-CAP investigators & the Ecraid operational team: jamanetwork.com/journals/jam...

Very pleased to announce a new speaker at our 'Better Methods' course in Athens: Prof. Sotirios Tsiodras! The programme will be updated shortly to reflect his topic. Registration remains open for this unique learning experience for early-career investigators: www.escmid.org/event-detail...

💡New publication! Researchers from #ECRAIDBase and ADVANCE-ID (NUS) have co-authored an article analysing the Personalised Randomised Controlled Trial (#PRACTicalTrial) design. 📖 bit.ly/45GgWUT #ResearchCollaboration #HORIZON2020 @advance-id.bsky.social @horizoneu.bsky.social @hug-ge.bsky.social

#DKY that in our post-grad course you can choose between two tracks, join parallel workshops, discuss real-world cases, & network with your peers? 💡 👀Check out the programme, apply for an attendance grant, or register directly to secure your place! ➡️ bit.ly/44a1tdn #IDSky #ResearchSky #Education

Proud of our partners at University of Geneva for having published an ECRAID-Base article investigating additional analysis methods for the novel Personalised Randomised Controlled Trial (PRACTical) design in @springernature.com: 👉 www.ecraid.eu/projects/ecr...

REMAP-CAP has published a paper in @springernature.com's Intensive Care Medicine Journal investigating whether hydrocortisone improves mortality in severe community-acquired pneumonia 👉 link.springer.com/article/10.1... #Pneumonia #ClinicalTrials #REMAPCAP

📩Check our latest newsletter for: highlights from our recent meeting with key primary care representatives, new collaborations (VAC4EU) and upcoming educational opportunities. 👉🏽Registration is open for the Postgraduate course in Athens! 📫Stay informed, subscribe now: bit.ly/EcraidJune25

Diagnosing & treating infections in #ICUs is complex due to the need for rapid intervention and growing antibiotic resistance. Our head of CLIN-Net Miranda Hopman is at the Intensive Medicine Congress in Lisbon to discuss future collabos & share expertise on building a 'warm-base' research network.

Join this webinar organised by Ecraid & the European Respiratory Society, tackling adaptive clinical trials designs in the setting of a respiratory infection. Info & registration 👉 ecraid.eu/news/webinar... This webinar concludes the Ecraid Training Modules on Adaptive Clinical Trial Designs.

👩‍🍼 Every year, ~400k babies in Europe are born preterm and require admission to a NICU. Ecraid is proud to be part of the #NeoDeco study, which aims to determine if optimised #kangaroocare can reduce resistant bacterial colonization, severe #neonatalinfections and #sepsis in preterm infants in NICUs.

Are you an early-career investigator in #InfectiousDiseases or #ClinicalMicrobiology? This course might benefit you! Expand your expertise & your network! Focus: new developments in methods; special emphasis on clinical trials; & use participants’ projects as examples. 👉 ecraid.eu/news/postgra...

💡 Why is a strong #primarycare research network critical to Europe’s response? Because it brings research closer to communities - enabling faster, smarter & more coordinated action when it matters most. Read about Europe’s primarycare network & its recent meeting on 🔗 www.ecraid.eu/news/collabo...

🎙️Join this live #REVIVE webinar from @gardp.bsky.social on post-licensing clinical trials for advancing the use of antimicrobials - moderated by Ecraid's STAT-Net Holly Jackson from Geneva University Hospital! Will you tune in? 🎧

The world celebrates International Clinical Trials Day to commemorate research professionals. 🔬 👉🏽Ecraid plays a key role in ID research and today we’re featuring the valued members of our operations team. Our teams are powered by the commitment of driving clinical research forward! #CTD2025

We’re excited to collaborate with VAC4EU to advance #vaccineresearch. The new partnership will assess the potential of leveraging our ongoing #observationalstudies to evaluate #vaccineeffectiveness and real-world impact. 💉 www.ecraid.eu/news/ecraid-... #clinicalresearch #vaccines

📩Our May newsletter highlights the inspiring conversations with the research community at ESCMID Global & Ecraid's scientific contributions in the field of ID. ❗Educational opportunity: registration is open for the Postgraduate course. Check it out! Stay informed, subscribe now: bit.ly/May-News-25

🩺 Happy Nurses Day! 💙 We are incredibly grateful for the nurses who work alongside us. Be it caring for patients in clinical trials, ensuring ethical standards, or contributing to life-saving discoveries, your impact is immeasurable! #NursesDay #ClinicalResearch

We are pleased to host our #primarycarenetwork teams in Utrecht to discuss ongoing studies on respiratory illness, successes and learnings & strategies to improve trial efficiency, recruitment and sustain impact. Thank you to all participating teams for your insights, collaboration and dedication!

The #ECRAIDPrime study is pleased to announce the addition of a third treatment to its ongoing adaptive platform trial in #primarycare and a key component of Europe’s #pandemicpreparedness. Read more on ecraid.eu/news/ecraid-...

That’s a wrap on ESCMID Global 2025! 🙌🏽 Thank you for an incredible event, it’s been inspiring to connect with so many brilliant experts contributing to drive innovation in infectious diseases. We look forward to seeing you at ESCMID next year! Join the movement: ecraid.eu @escmid.bsky.social

👏🏽Congratulations to Prof. @marionkoopmans.bsky.social for receiving the ESCMID Award for Outstanding Contributions in the Field of Infection! We’re proud to celebrate Professor Koopmans, a key member of the Ecraid Coordinating Committee, for receiving this award! Read more: bit.ly/AwardESCMID

👉🏽Day 3 at #ESCMIDGlobal brought incredible discussions with existing & new partners and saw members of the Ecraid network presenting their posters @jacopogarlasco.bsky.social. 🔎Don’t miss other great sessions co-organised by Ecraid & more poster presentations tomorrow: www.ecraid.eu/news/see-you...

👉🏽Wrapping up an insightful day 2 at ESCMID Global! We had great conversations, insights and built new valuable connections to our clinical research network. See you tomorrow at booth E70, Hall B. Don’t miss out Ecraid’s co-organised sessions: www.ecraid.eu/news/see-you...

👉🏽Day 1 at ESCMID Global - what a great start! We had interesting conversations, looking forward to more connections tomorrow at Booth E70, Hall B. Don’t miss out some great sessions tomorrow such as 'New tools in acute bacterial infections and sepsis' presented by @lenniederde.bsky.social.